[Surgical therapeutic concept of immune thyropathy]
- PMID: 3683036
- DOI: 10.1007/BF01259433
[Surgical therapeutic concept of immune thyropathy]
Abstract
73 patients with Graves' disease, surgically treated from 1975-1986, were investigated retrospectively. 43 patients, treated by subtotal thyroidectomy (Enderlen-Hotz) and a bilateral thyroid remnant of a total of about 8-12 g, were compared with 30 patients, treated by a modified subtotal thyroidectomy leaving a unilateral thyroid remnant of about 4-8 g, with respect to preoperative duration of disease, indications for surgical treatment, weight of resected specimens, operative complications and postoperative thyroid function. Surgical complications were similar in both groups. After subtotal thyroidectomy 14/43 patients (33%) displayed either recurrent hyperthyroidism (9/43, 21%) or local recurrence of Graves' goiter (3/43, 7%) or both (2/43, 5%). The modified subtotal resected group showed no recurrences of the disease. After subtotal thyroidectomy 11 patients were euthyroid without thyroid medication (26%) compared to only two patients (7%) after the modified procedure of subtotal thyroid resection. To prevent recurrences of goiter as well as hyperthyroidism and, on the other hand, to achieve euthyroid function postoperatively without need for thyroid replacement therapy, subtotal thyroidectomy with a small thyroid remnant of about 4-8 g is recommended for all patients with large goiter and a chronic recurrent course of the disease or with iodine induced thyrotoxicosis. Patients with non-recurrent Graves' disease but large goiter probably benefit from subtotal thyroidectomy with a larger thyroid remnant of about 8-12 g.
Similar articles
-
The long-term outcomes of thyroid function after subtotal thyroidectomy for Graves' hyperthyroidism.J Surg Res. 2017 Dec;220:112-118. doi: 10.1016/j.jss.2017.06.091. Epub 2017 Jul 26. J Surg Res. 2017. PMID: 29180171
-
Surgery for Graves' disease: total versus subtotal thyroidectomy-results of a prospective randomized trial.World J Surg. 2000 Nov;24(11):1303-11. doi: 10.1007/s002680010216. World J Surg. 2000. PMID: 11038198 Clinical Trial.
-
Preoperative change of thyroid stimulating hormone receptor antibody level: possible marker for predicting recurrent hyperthyroidism in patients with Graves' disease after subtotal thyroidectomy.World J Surg. 1996 Sep;20(7):801-6; discussion 806-7. doi: 10.1007/s002689900122. World J Surg. 1996. PMID: 8678954
-
Treatment of patients with Graves' disease and the appropriate extent of thyroidectomy.Best Pract Res Clin Endocrinol Metab. 2019 Aug;33(4):101319. doi: 10.1016/j.beem.2019.101319. Epub 2019 Aug 31. Best Pract Res Clin Endocrinol Metab. 2019. PMID: 31530446 Review.
-
[Morbidity after subtotal and total thyroidectomy in patients with Graves' disease: the basis for decision-making regarding surgical indication and extent of resection].Z Arztl Fortbild Qualitatssich. 2004 May;98 Suppl 5:45-53. Z Arztl Fortbild Qualitatssich. 2004. PMID: 15255313 Review. German.
Cited by
-
European endocrine surgery in the 150-year history of Langenbeck's Archives of Surgery.Langenbecks Arch Surg. 2010 Apr;395 Suppl 1:43-55. doi: 10.1007/s00423-010-0615-4. Epub 2010 Mar 9. Langenbecks Arch Surg. 2010. PMID: 20217121